Mabwell

Mabwell Biotech is a cutting-edge biopharmaceutical company based in the Shanghai Zhangjiang Hi-Tech Park, focusing on pioneering breakthrough therapies in oncology, autoimmunity, infectious diseases, and ophthalmology. Established in 2017, the company has initiated nine new biopharmaceutical R&D and production ventures, specializing in the development and manufacturing of macromolecular drugs, including therapeutic monoclonal antibodies and long-acting recombinant proteins. With a diverse pipeline comprising over thirty drug varieties at different developmental stages for addressing tumor, autoimmunity, anti-infection, and ophthalmic diseases, it has made significant progress, with six drugs reaching the clinical stage and three currently in Phase III clinical trials.

Amid its rapid growth, Mabwell Biotech secured a substantial $278.50M Series A investment on 29 April 2020. The investment was led by a consortium of prominent investors, including Loyal Valley Capital, Oriental Fortune Capital, Shiyu Capital, Haitong Leading Capital Management, Sincere Capital, Founder H Fund, Huajin Capital, Huarong Rongde Asset Management, and Winfast Holding. This injection of capital is expected to propel the company's innovative research and development initiatives and further advance its position in the biopharmaceutical industry.